domingo, 15 de diciembre de 2013

Clinical Utility of a Biopsy-Based Cell Cy... [Curr Med Res Opin. 2013] - PubMed - NCBI

Clinical Utility of a Biopsy-Based Cell Cy... [Curr Med Res Opin. 2013] - PubMed - NCBI

2013 Dec 10. [Epub ahead of print]

Clinical Utility of a Biopsy-Based Cell Cycle Gene Expression Assay in Localized Prostate Cancer.


Carolina Urologic Research Center, Myrtle Beach, SC;


Abstract Objective: The CCP signature test (Prolaris) quantifies a patient's risk of disease progression and prostate cancer-specific mortality using a gene expression-based cell cycle progression (CCP) score. This study evaluated the potential clinical utility of the CCP test in a U.S.-based clinical setting. Methods: Urologists who participated in a prospective clinical study were sent a retrospective questionnaire to assess the value of the CCP test result. Fifteen board-certified urologists participated in the study, representing 15 distinct community urology group practices. Questionnaires were received for 294 evaluable patients. All patients had localized prostate cancer (T1-T3b, N0, M0). Results: Physicians found the CCP score valuable and indicated that 55% of tests generated a mortality risk that was either higher or lower than expected. Physicians also indicated that 32% of test results would lead to a definite or possible change in treatment. The data suggest that the test would have the net effect of shifting patients from more aggressive treatment to more conservative treatment. This was evidenced by the significant association between change in treatment and lower CCP scores (p<0 .002="" 10="" 62="" a="" actual="" adds="" aggressive="" and="" as="" assessment="" by="" cancer="" ccp="" change="" conclusions:="" conservative="" costs="" could="" decreasing="" definite="" disease="" estimated="" expected.="" expected="" fact="" for="" had="" healthcare="" higher="" in="" information="" is="" lead="" less="" likelihood="" likely="" limitations:="" localized="" lower="" management.="" meaningful="" measured="" morbidity="" more="" mortality="" new="" not="" of="" only="" or="" overtreatment="" particularly="" patient="" patients.="" patients="" payers="" physician="" portion="" possible="" prostate="" real-world="" reduce="" retrospectively-assessed="" risk="" risks="" score="" shifting="" significant="" study="" system.="" test="" tested="" tests="" than="" that="" the="" this="" to="" towards="" treatment.="" treatment="" use="" versus="" with="">

[PubMed - as supplied by publisher]

No hay comentarios:

Publicar un comentario